Aligos Therapeutics
ALGS | NASDAQ
$1.66
-$0.44 (-20.95%)
At close: Nov 16, 2026, 4:00 PM ET
$1.67
+$0.01 (+0.60%)
After-hours:
Nov 16, 2026, 7:31 PM ET
-20.95%
(1D)No price chart data available for 1D timeframe.
Rating
39.2
-8.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #546/1021 (Top 53%)
Key Statistics
Market Data
Market Cap $17.37M
1D Range
1.61 2.00
52W Range
1.61 13.30
Valuation (TTM)
PE -0.26
PB 1.54
EV/EBITDA 0.03
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $20.00
Cash Flow
FCF Yield -395.4%
SBC Adj. FCF Yield -426.6%
SBC Impact -7.9%
Margins
Gross Margin 99.2%
Operating Margin -235.6%
FCF Margin -223.1%
Growth (CAGR)
Revenue 3Y | 5Y 23.4% |
50.5%
Dil EPS 3Y | 5Y -4.4% |
-31.2%
FCF 3Y | 5Y 10.6% |
7.2%
Returns
ROA -140.5%
ROE -206.3%
ROIC -251.6%
Financial Health
Net Cash
$19.19M
Current Ratio 1.77
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidat...
Sector Healthcare
Industry Biotechnology
Employees 82
IPO Date Oct 16, 2020
Website www.aligos.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 6, 2026
EPS
-$2.09
Beat +8.33%
YoY:
+31.25% REV
$2.87M
Miss -40.85%
YoY:
+287.18%Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$20.00
Upside
+1104.82%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ALGS